June 27, 2026 02:56 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Pune fort murder case: Siya Goyal's brother says family would have called off marriage if she had objected | Donald Trump gets a road named after him in India, says 'Thank You!' | Fresh setback for Gautam Adani? US judge asks DoJ to justify dropping criminal charges | Ram Mandir Trust chief Champat Rai resigns as alleged donation siphoning row escalates | Ram Mandir fund row deepens: 8 arrested days after BJP called allegations 'false narrative' | 'Who tied the hands of CBI?': Calcutta HC on RG Kar case; victim's mother, now BJP MLA, says she is 'deeply disturbed' | Construction comes to a standstill at nearly 700 Kolkata projects after Taratala warehouse tragedy kills 15 | World Cup shocker! Ecuador stun Germany 2-1, storm into Round of 32 | Iran-US conflict: Cargo vessel hit near Strait of Hormuz, UN agency pauses evacuation operations | Amazon's massive India bet! Andy Jassy announces $48 billion investment after meeting PM Modi
Russia Vaccine

Russia's RDIF confirms plans to sell 100mln doses of COVID-19 vaccine to India

| @indiablooms | Sep 16, 2020, at 09:33 pm

Moscow/Sputnik: The Russian Direct Investment Fund (RDIF) confirmed on Wednesday reaching an agreement to deliver 100 million doses of the Russian COVID-19 vaccine Sputnik V to India, specifying that the deal was reached with India's Dr. Reddy's.

Earlier in the day, a source told Sputnik that the RDIF would deliver 100 million doses of the vaccine to an Indian pharmaceutical company.

"The RDIF, Russia’s sovereign wealth fund, and Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddy’s 100 million doses of the vaccine," the RDIF said in a press release.

Deliveries could start in late 2020, the RDIF added.

A request for approval for the Phase 3 trials in India "will be filed shortly" to India's drug regulator, a RDIF spokesman told reporters.

"We are pleased to partner with RDIF to bring the vaccine to India. The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India," Dr. Reddy's Co-Chairman and Managing Director G. V. Prasad said, as quoted in the press release.

The RDIF is pleased to reach the agreement with the Indian company, RDIF CEO Kirill Dmitriev said.

"Dr. Reddy’s has had a very well established and respected presence in Russia for over 25 years and is one of the leading pharmaceutical companies in India. India is amongst most severely impacted countries from COVID 19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID 19. RDIF partners will receive an effective and safe drug to fight the coronavirus," Dmitriev said.

In August, Russia registered the world’s first COVID-19 vaccine, developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.